Detail akcie Atos SA online

Business Summary: Aton SA, formerly known as Hybrigenics SA is France-based Company engaged in the biotechnological sector. It specializes in the research and development of drugs intended for cancer treatment and supplies scientific services in the protein interaction field. The Company is specialized in the research and development (R&D) of drugs to fight cancer. It is organized in two units: Hybrigenics Pharma for internal R&D, which develops a research program aimed at such diseases as melanoma and prostate cancer; and Hybrigenics Services for commercial business, mainly engaged in protein interaction information and solutions. Hybrigenics SA’s main development program is based on inecalcitol, a vitamin D analogue, for prostate cancer treatment. It operates through Hybrigenics Corporation and Imaxio.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Aton SA revenues increased from EUR2K to EUR382K. Net loss increased from EUR564K to EUR18.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Total Financial Charges increase from EUR60K to EUR13M (expense), Special Expense increase from EUR9K (income) to EUR5.3M (expense).